BioNet News, Covid-19, Press Releases 16 Nov 2022 Phase 2 trial of ChulaCov19 BNA159 mRNA Vaccine to start in Australia ChulaCov19 BNA159 is a COVID-19 mRNA vaccine developed by Chulalongkorn University and produced by BioNet ChulaCov19 mRNA vaccine was found… Supachai
BioNet News, Covid-19, Press Releases 21 Mar 2022 Technovalia, Sypharma and BioNet announce the establishment of Genetis, the first Australian Vaccine Development and Manufacturing Hub for mRNA, DNA and recombinant vaccines. Supachai
BioNet News, Covid-19 01 Feb 2022 BioNet earns up to $16.9M from CEPI for studies, production and analysis of variant-proof SARS-CoV-2 vaccine Drawing from a $200 million program meant to stimulate the development of vaccines with broad betacoronavirus protection, the Coalition for… Supachai
BioNet News, Covid-19 26 Jan 2022 CEPI partners with BioNet to expand variant-proof vaccine programme OSLO, Norway, 25 January 2022: CEPI, the Coalition for Epidemic Preparedness Innovations, today announced the latest award under its $200m programme, launched… Supachai
BioNet News, Covid-19, Press Releases 18 Jan 2022 COVALIA study update: Interim Safety Results from needle-free SARS-CoV2 DNA vaccine phase 1 trial Melbourne 17 January 2022 –Technovalia, an Australian biotech vaccine developer today announced the interim safety results of the ongoing phase… Supachai
BioNet News, Covid-19 16 Nov 2021 Vaccine partnership results in optimized mRNA process, says BioNet BioNet’s product development of genetic vaccine know-how integrated with BIA’s chromatographic columns for mRNA purification has produced a high-yield mRNA… Supachai
BioNet News, Covid-19, Press Releases 03 Nov 2021 BioNet and Sartorius’ company BIA Separations collaborate on production process development of mRNA vaccines Ajdovščina, Slovenia & Bangkok, Thailand, 02 November 2021: BioNet, a leading biotech company manufacturing genetically engineered vaccines, and BIA Separations,… Supachai
BioNet News, Covid-19, Press Releases 02 Jul 2021 COVALIA study update: first healthy volunteers dosed in needle-free SARS-CoV2 DNA vaccine phase 1 trial Melbourne _ 30th June 2021 – Australian biotech company Technovalia is pleased to announce that the first volunteers have… Supachai
BioNet News, Covid-19, Press Releases 25 Jun 2021 The COVALIA trial has commenced with the first injections of COVIGEN in Australia Partnership to test SARS-CoV2 DNA vaccine in healthy Australians Australian researchers will this week commence the first Phase 1 human… Supachai
BioNet News, Covid-19, Press Releases 24 Jun 2021 New needle-free COVID-19 vaccine trial A new COVID-19 vaccine trial has started in Australia which doesn't involve needle injections. Supachai